Cystitis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) No edit summary |
Usama Talib (talk | contribs) |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
In Cystitis Disease and pathogen specific therapies are much more cost effective than broad spectrum therapies used for symptomatic treatment. [[Hyaluronon]] therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a [[Urinary tract infection]].<ref name="pmid23921624">{{cite journal| author=Riedl C, Engelhardt P, Schwarz B| title=Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines. | journal=Clin Drug Investig | year= 2013 | volume= 33 | issue= 10 | pages= 737-42 | pmid=23921624 | doi=10.1007/s40261-013-0119-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23921624 }} </ref> | |||
==References== | ==References== | ||
Revision as of 18:24, 12 January 2017
|
Cystitis Microchapters | |
|
Diagnosis | |
|
Treatment | |
|
Case Studies | |
|
Cystitis cost-effectiveness of therapy On the Web | |
|
American Roentgen Ray Society Images of Cystitis cost-effectiveness of therapy | |
|
Risk calculators and risk factors for Cystitis cost-effectiveness of therapy | |
Overview
In Cystitis Disease and pathogen specific therapies are much more cost effective than broad spectrum therapies used for symptomatic treatment. Hyaluronon therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a Urinary tract infection.[1]
References
- ↑ Riedl C, Engelhardt P, Schwarz B (2013). "Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines". Clin Drug Investig. 33 (10): 737–42. doi:10.1007/s40261-013-0119-4. PMID 23921624.